| Size | Price | |
|---|---|---|
| 500mg | ||
| 1g | ||
| Other Sizes |
| ADME/Pharmacokinetics |
Absorption, Distribution and Excretion
When used in combination with other ingredients in suppository form, absorption into the bloodstream is minimal. However, applying creams or ointments to open wounds or skin may result in absorption and entry into the bloodstream. Metabolism/Metabolites Following oral administration of aescin (100 mg/kg) to rats, plasma, urine, feces, and bile samples were collected to screen for metabolites. A total of 19 metabolites were identified (10 phase I metabolites and 9 phase II metabolites). The study also found that after oral administration of aescin, it can be metabolized in vivo to aescinol via deglycosylation, and aescinol was detected in all biological samples. Biological Half-Life The absorption half-life is approximately 1 hour, and the elimination half-life is approximately 20 hours. |
|---|---|
| References |
|
| Additional Infomation |
Aescin is a hydroxycoumarin, a 6-O-β-D-glucoside of aescin. It has antioxidant and metabolic effects. It is a β-D-glucoside and hydroxycoumarin, functionally related to aescin. Aescin is found in barley. Vitamin C2 is generally considered a bioflavonoid, associated with vitamin P. Aescin is a glucoside naturally found in the dark green resin of Aesculus hippocastanum, Aesculus californica, and Daphne mezereum. Aescin belongs to the glycoside family. These are carbohydrate derivatives in which one glycosyl group is linked to another glycosyl group via a C-, S-, N-, O-, or Se-glycosidic bond through its non-glycosyl carbon atom. Aescin has been reported in Gardenia jasminoides, Ixeridium laevigatum, and other organisms with relevant data. It is a derivative of coumarin, with the molecular formula C15H16O9. See also: Aesculus (part); Aesculus bark (part). Pharmacological Indications Aesculin is sometimes used as a vascular protectant. It is also used in microbiology laboratories to aid in the identification of bacterial species (especially Enterococci and Listeria), as all Group D Streptococcus strains can hydrolyze aesculin in 40% bile. Mechanism of Action Aesculin's primary function is to protect capillaries by improving their permeability and fragility. It has been reported to inhibit catabolic enzymes such as hyaluronidase and collagenase, thereby maintaining the integrity of perivascular connective tissue. Aesculin also exhibits good antioxidant properties, protecting triglycerides from autoxidation at high temperatures. These antioxidant properties may also explain its anti-inflammatory activity, making it an ideal product for after-sun care.
Pharmacodynamics Topical application of aescin can increase "capillary density" (the number of open, flowing capillaries per unit surface area) and improve the morphology of the smallest vessels. |
| Molecular Formula |
C30H38O21
|
|---|---|
| Molecular Weight |
367.31
|
| Exact Mass |
358.089
|
| CAS # |
66778-17-4
|
| Related CAS # |
Esculin;531-75-9
|
| PubChem CID |
5281417
|
| Appearance |
Typically exists as solid at room temperature
|
| Density |
0.791 g/mL at 20 °C
|
| Melting Point |
203-205 °C
|
| LogP |
-0.6
|
| Hydrogen Bond Donor Count |
5
|
| Hydrogen Bond Acceptor Count |
9
|
| Rotatable Bond Count |
3
|
| Heavy Atom Count |
24
|
| Complexity |
495
|
| Defined Atom Stereocenter Count |
5
|
| SMILES |
O1[C@]([H])([C@@]([H])([C@]([H])([C@@]([H])([C@@]1([H])C([H])([H])O[H])O[H])O[H])O[H])OC1=C(C([H])=C2C(C([H])=C([H])C(=O)O2)=C1[H])O[H].O1[C@]([H])([C@@]([H])([C@]([H])([C@@]([H])([C@@]1([H])C([H])([H])O[H])O[H])O[H])O[H])OC1=C(C([H])=C2C(C([H])=C([H])C(=O)O2)=C1[H])O[H].O([H])[H].O([H])[H].O([H])[H]
|
| InChi Key |
XHCADAYNFIFUHF-TVKJYDDYSA-N
|
| InChi Code |
InChI=1S/C15H16O9/c16-5-10-12(19)13(20)14(21)15(24-10)23-9-3-6-1-2-11(18)22-8(6)4-7(9)17/h1-4,10,12-17,19-21H,5H2/t10-,12-,13+,14-,15-/m1/s1
|
| Chemical Name |
7-hydroxy-6-[(2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxychromen-2-one
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.7225 mL | 13.6125 mL | 27.2250 mL | |
| 5 mM | 0.5445 mL | 2.7225 mL | 5.4450 mL | |
| 10 mM | 0.2722 mL | 1.3612 mL | 2.7225 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
